Compounds > imipenem, anhydrous
Page last updated: 2024-08-26

imipenem, anhydrous and B cepacia Infection

imipenem, anhydrous has been researched along with B cepacia Infection in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (20.00)18.2507
2000's2 (40.00)29.6817
2010's2 (40.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Alba, L; Chen, Y; Garber, E; Saiman, L; Tabibi, S; Zhou, J1
Chan, YY; Deris, ZZ; Habsah, H; Noraida, R; Ravichandran, M; Rosliza, AR; Tan, GC; Van Rostenberghe, H1
Barbeito Castiñeiras, G; Martín Romero Domínguez, M; Martínez-Lamas, L; Palacios Bartolomé, A; Pérez Del Molino Bernal, ML; Rabade Castedo, C1
Bal, C; Bauernfeind, A; Ersöz, G; Otağ, F; Salcioğlu, M; Schneider, I1
Bingen, E; Bonacorsi, S; Fitoussi, F; Lhopital, S1

Other Studies

5 other study(ies) available for imipenem, anhydrous and B cepacia Infection

ArticleYear
Antimicrobial susceptibility and synergy studies of Burkholderia cepacia complex isolated from patients with cystic fibrosis.
    Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:3

    Topics: Anti-Bacterial Agents; Burkholderia cepacia complex; Burkholderia Infections; Cystic Fibrosis; Drug Resistance, Multiple, Bacterial; Drug Synergism; Humans; Microbial Sensitivity Tests

2007
First isolation of Burkholderia tropica from a neonatal patient successfully treated with imipenem.
    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2010, Volume: 14, Issue:1

    Topics: Anti-Bacterial Agents; Bacteremia; Burkholderia; Burkholderia Infections; Fatal Outcome; Humans; Imipenem; Immunocompromised Host; Infant, Newborn; Infant, Premature; Male; Risk Factors

2010
[Pandoraea sputorum colonization in a patient with cystic fibrosis].
    Archivos de bronconeumologia, 2011, Volume: 47, Issue:11

    Topics: Anti-Bacterial Agents; Bronchiectasis; Burkholderia cepacia complex; Burkholderia Infections; Child; Cystic Fibrosis; Cytokines; Drug Resistance, Multiple, Bacterial; Female; Follow-Up Studies; Humans; Imipenem; Pneumonia, Bacterial; Pseudomonas Infections; Sputum; Superinfection; Virulence

2011
Nosocomial bloodstream infections with Burkholderia stabilis.
    The Journal of hospital infection, 2005, Volume: 59, Issue:1

    Topics: Adolescent; Adult; Aged; Bacteremia; Bacterial Typing Techniques; Burkholderia; Burkholderia Infections; Ciprofloxacin; Cross Infection; Drug Resistance, Bacterial; Drug Therapy, Combination; Hospital Mortality; Hospitals, University; Humans; Imipenem; Infection Control; Intensive Care Units; Male; Middle Aged; Opportunistic Infections; Random Amplified Polymorphic DNA Technique; Retrospective Studies; Risk Factors; Treatment Outcome; Turkey

2005
Comparative in vitro activities of meropenem, imipenem, temocillin, piperacillin, and ceftazidime in combination with tobramycin, rifampin, or ciprofloxacin against Burkholderia cepacia isolates from patients with cystic fibrosis.
    Antimicrobial agents and chemotherapy, 1999, Volume: 43, Issue:2

    Topics: Burkholderia cepacia; Burkholderia Infections; Ceftazidime; Ciprofloxacin; Cystic Fibrosis; Drug Synergism; Drug Therapy, Combination; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Penicillins; Piperacillin; Rifampin; Thienamycins; Tobramycin

1999